List of Studies ( Metabolite:Ala-Ala-Pro)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
|---|---|---|---|---|---|---|---|
| ST003024 | AN004958 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 | Bacterial cells | Bacteria | Monash Institute of Pharmaceutical Sciences | peak height | |
| ST003036 | AN004977 | Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 | Bacterial cells | Pseudomonas aeruginosa | Bacterial infection | Monash Institute of Pharmaceutical Sciences | peak height |
| ST003521 | AN005782 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | peak height |
| ST003521 | AN005783 | Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii | Bacterial cells | Acinetobacter baumannii | Bacterial infection | Monash University | peak height |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
| ST002107 | AN003447 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | relative intensity |
